XAIR Stock Forecast & Price Target

Beyond Air Inc. reported strong quarterly results for the period ending June 30, 2025, with revenue increasing by 157% year-over-year to $1.8 million, fueled by heightened demand for its LungFit PH system in both domestic and international markets. The company achieved a notable improvement in gross profit, turning positive at $0.2 million, indicating a shift in its growth trajectory. Furthermore, a national group purchasing agreement with Premier, Inc. significantly enhances Beyond Air's market access by connecting it to over 4,350 hospitals and health systems, supporting the potential for accelerated revenue growth and broader technology adoption.

Beyond Air Inc's recent financial report indicates a notable gross loss of $0.3 million, representing an improvement from $1.1 million a year prior, yet the company continues to face significant challenges with a net loss of $7.9 million, or $1.25 per share. Although the reduction in R&D and SG&A expenses to $2.5 million and $4.9 million respectively suggests cost management efforts, the persistent net cash burn of $4.7 million raises concerns about the company's liquidity and sustainability. Furthermore, the potential adverse effects associated with nitric oxide therapy on cellular respiration and tissue health could impede the firm's ability to gain regulatory approvals and market acceptance for its intended treatments.